drugset / Trial / NCT03236649
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Phase 3
Terminated
89 enrolled
Beijing Shenogen Biomedical Co., Ltd
307 Hospital of PLA · collabAffiliated Cancer Hospital & Institute of Guangzhou Medical University · collabAnhui Provincial Hospital · collabBeijing Hospital · collabBeijing YouAn Hospital · collabCancer Institute and Hospital, Chinese Academy of Medical Sciences · collabChinese PLA General Hospital · collabEastern Theater General Hospital,QinHuai District Medical Area · collabFirst Affiliated Hospital of Harbin Medical University · collabFirst People's Hospital of Foshan · collabFudan University · collabGeneral Hospital of Chinese Armed Police Forces · collabGuang'anmen Hospital of China Academy of Chinese Medical Sciences · collabHebei Medical University Fourth Hospital · collabHenan Cancer Hospital · collabHunan Cancer Hospital · collabJilin Provincial Tumor Hospital · collabJinan Central Hospital · collabLinyi Cancer Hospital · collabNanfang Hospital, Southern Medical University · collabPeking University Cancer Hospital & Institute · collabThe Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China · collabThe First Affiliated Hospital of Anhui Medical University · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe First Affiliated Hospital of Soochow University · collabThe First Affiliated Hospital with Nanjing Medical University · collabThe First Hospital of Jilin University · collabTianjin Medical University Cancer Institute and Hospital · collabTongji Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary efficacy index of this study is to compare the OS of the two groups.
Timeline
- Start
- 2017-09-20
- Primary completion
- 2022-02-08
- Completion
- 2022-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icaritin | Small molecule | 600 mg | Oral |
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |